OrbiMed’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14M | Buy |
+39,900
| New | +$14.2M | 0.28% | 68 |
|
|
2025
Q2 | – | Sell |
-44,200
| Closed | -$13.8M | – | 103 |
|
|
2025
Q1 | $13.8M | Buy |
+44,200
| New | +$13.1M | 0.33% | 54 |
|
|
2024
Q4 | – | Sell |
-252,300
| Closed | -$81.3M | – | 120 |
|
|
2024
Q3 | $81.3M | Buy |
252,300
+117,400
| +87% | +$38.4M | 1.48% | 20 |
|
|
2024
Q2 | $42.1M | Buy |
134,900
+71,500
| +113% | +$21M | 0.83% | 36 |
|
|
2024
Q1 | $18M | Sell |
63,400
-63,900
| -50% | -$18.7M | 0.33% | 70 |
|
|
2023
Q4 | $36.7M | Hold |
127,300
| – | – | 0.73% | 48 |
|
|
2023
Q3 | $34.2M | Hold |
127,300
| – | – | 0.73% | 51 |
|
|
2023
Q2 | $28.3M | Buy |
127,300
+50,600
| +66% | +$11.7M | 0.51% | 58 |
|
|
2023
Q1 | $18.5M | Buy |
+76,700
| New | +$18.8M | 0.36% | 70 |
|
|
2022
Q3 | – | Sell |
-57,100
| Closed | -$13.9K | – | 133 |
|
|
2022
Q2 | $13.9K | Hold |
57,100
| – | – | 0.25% | 75 |
|
|
2022
Q1 | $13.8M | Hold |
57,100
| – | – | 0.22% | 86 |
|
|
2021
Q4 | $12.8M | Hold |
57,100
| – | – | 0.17% | 107 |
|
|
2021
Q3 | $12.1M | Hold |
57,100
| – | – | 0.13% | 118 |
|
|
2021
Q2 | $13.9M | Sell |
57,100
-34,400
| -38% | -$8.46M | 0.14% | 112 |
|
|
2021
Q1 | $22.8M | Hold |
91,500
| – | – | 0.21% | 94 |
|
|
2020
Q4 | $21M | Hold |
91,500
| – | – | 0.18% | 99 |
|
|
2020
Q3 | $23.3M | Hold |
91,500
| – | – | 0.29% | 81 |
|
|
2020
Q2 | $21.6M | Sell |
91,500
-13,700
| -13% | -$3.13M | 0.3% | 74 |
|
|
2020
Q1 | $21.3M | Sell |
105,200
-16,900
| -14% | -$3.69M | 0.36% | 63 |
|
|
2019
Q4 | $29.4M | Hold |
122,100
| – | – | 0.42% | 56 |
|
|
2019
Q3 | $23.6M | Hold |
122,100
| – | – | 0.45% | 55 |
|
|
2019
Q2 | $22.5M | Hold |
122,100
| – | – | 0.35% | 66 |
|
|
2019
Q1 | $23.2M | Hold |
122,100
| – | – | 0.36% | 66 |
|
|
2018
Q4 | $23.8M | Sell |
122,100
-29,500
| -19% | -$5.76M | 0.44% | 63 |
|
|
2018
Q3 | $31.4M | Buy |
151,600
+27,500
| +22% | +$5.42M | 0.38% | 68 |
|
|
2018
Q2 | $22.9M | Sell |
124,100
-321,210
| -72% | -$56.8M | 0.27% | 84 |
|
|
2018
Q1 | $75.9M | Sell |
445,310
-851,790
| -66% | -$156M | 0.94% | 35 |
|
|
2017
Q4 | $226M | Buy |
1,297,100
+44,000
| +4% | +$7.79M | 2.85% | 7 |
|
|
2017
Q3 | $234M | Sell |
1,253,100
-49,600
| -4% | -$8.79M | 2.23% | 11 |
|
|
2017
Q2 | $224M | Sell |
1,302,700
-135,600
| -9% | -$22.1M | 2.35% | 11 |
|
|
2017
Q1 | $236M | Sell |
1,438,300
-893,500
| -38% | -$148M | 2.67% | 10 |
|
|
2016
Q4 | $341M | Sell |
2,331,800
-104,900
| -4% | -$15.8M | 4.34% | 5 |
|
|
2016
Q3 | $406M | Sell |
2,436,700
-596,800
| -20% | -$101M | 4.63% | 3 |
|
|
2016
Q2 | $462M | Buy |
3,033,500
+157,500
| +5% | +$24.5M | 4.82% | 2 |
|
|
2016
Q1 | $431M | Sell |
2,876,000
-45,000
| -2% | -$6.69M | 4.54% | 3 |
|
|
2015
Q4 | $474M | Sell |
2,921,000
-92,000
| -3% | -$14.5M | 4.29% | 2 |
|
|
2015
Q3 | $417M | Buy |
3,013,000
+132,000
| +5% | +$20.8M | 4.21% | 3 |
|
|
2015
Q2 | $442M | Sell |
2,881,000
-168,000
| -6% | -$26.9M | 3.7% | 7 |
|
|
2015
Q1 | $487M | Buy |
3,049,000
+341,000
| +13% | +$53.7M | 4.16% | 3 |
|
|
2014
Q4 | $431M | Buy |
2,708,000
+105,000
| +4% | +$16.4M | 4.12% | 3 |
|
|
2014
Q3 | $366M | Buy |
2,603,000
+358,000
| +16% | +$46.7M | 3.82% | 4 |
|
|
2014
Q2 | $266M | Sell |
2,245,000
-70,900
| -3% | -$8.21M | 3.12% | 6 |
|
|
2014
Q1 | $286M | Sell |
2,315,900
-199,400
| -8% | -$24.2M | 3.51% | 6 |
|
|
2013
Q4 | $287M | Sell |
2,515,300
-114,300
| -4% | -$13M | 4.22% | 5 |
|
|
2013
Q3 | $294M | Buy |
2,629,600
+10,200
| +0.4% | +$1.11M | 5.25% | 2 |
|
|
2013
Q2 | $258M | Buy |
+2,619,400
| New | +$272M | 5.48% | 1 |
|
Other funds holding AMGN
VCM
VPM
OrbiMed's AMGN Position: Q1 2026 in Review
OrbiMed opened a new position in Amgen (AMGN) in Q1 2026: 39,900 shares worth $14M. The stake represents 0.28% of the portfolio and ranks #68 among its holdings. This is a return to the name: OrbiMed previously reported a position in AMGN as recently as Q1 2025.
OrbiMed first reported a position in AMGN in Q2 2013 and has held it in 46 quarters since. The position peaked at $487M in Q1 2015. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- OrbiMed held 39,900 shares of Amgen worth $14M as of Q1 2026.
- Amgen was a new OrbiMed position in Q1 2026.
- Amgen made up 0.28% of OrbiMed's portfolio in Q1 2026, its #68 holding.
- OrbiMed first reported a position in Amgen in Q2 2013 and has held it in 46 quarters since.
- OrbiMed's Amgen position peaked at $487M in Q1 2015.
- 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.